These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21824435)

  • 1. Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model.
    Sivak O; Gershkovich P; Lin M; Wasan EK; Zhao J; Owen D; Clement JG; Wasan KM
    Lipids Health Dis; 2011 Aug; 10():135. PubMed ID: 21824435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model.
    Wasan EK; Gershkovich P; Zhao J; Zhu X; Werbovetz K; Tidwell RR; Clement JG; Thornton SJ; Wasan KM
    PLoS Negl Trop Dis; 2010 Dec; 4(12):e913. PubMed ID: 21151883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel oral amphotericin B formulation (iCo-010) remains highly effective against murine systemic candidiasis following exposure to tropical temperature.
    Wasan KM; Sivak O; Bartlett K; Wasan EK; Gershkovich P
    Drug Dev Ind Pharm; 2015; 41(9):1425-30. PubMed ID: 25170660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biodistribution and tissue toxicity of amphotericin B in mice following multiple dose administration of a novel oral lipid-based formulation (iCo-009).
    Gershkovich P; Sivak O; Wasan EK; Magil AB; Owen D; Clement JG; Wasan KM
    J Antimicrob Chemother; 2010 Dec; 65(12):2610-3. PubMed ID: 20861140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice.
    Gershkovich P; Wasan EK; Sivak O; Li R; Zhu X; Werbovetz KA; Tidwell RR; Clement JG; Thornton SJ; Wasan KM
    J Antimicrob Chemother; 2010 Mar; 65(3):535-7. PubMed ID: 20026611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and toxicity of a tropically stable lipid-based formulation of amphotericin B (iCo-010) in a rat model of invasive candidiasis.
    Ibrahim F; Gershkovich P; Sivak O; Wasan EK; Bartlett K; Wasan KM
    Int J Pharm; 2012 Oct; 436(1-2):318-23. PubMed ID: 22772485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of an oral and tropically stable lipid-based formulation of Amphotericin B (iCo-010) in an experimental mouse model of systemic candidiasis.
    Ibrahim F; Sivak O; Wasan EK; Bartlett K; Wasan KM
    Lipids Health Dis; 2013 Oct; 12():158. PubMed ID: 24164705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and tissue distribution of amphotericin B following oral administration of three lipid-based formulations to rats.
    Ibrahim F; Gershkovich P; Sivak O; Wasan EK; Wasan KM
    Drug Dev Ind Pharm; 2013 Sep; 39(9):1277-83. PubMed ID: 22989082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation.
    Gershkovich P; Wasan EK; Lin M; Sivak O; Leon CG; Clement JG; Wasan KM
    J Antimicrob Chemother; 2009 Jul; 64(1):101-8. PubMed ID: 19398459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral administration of amphotericin B nanoparticles: antifungal activity, bioavailability and toxicity in rats.
    Radwan MA; AlQuadeib BT; Šiller L; Wright MC; Horrocks B
    Drug Deliv; 2017 Nov; 24(1):40-50. PubMed ID: 28155565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodistribution and histopathology studies of amphotericin B sodium deoxycholate sulfate formulation following intratracheal instillation in rat models.
    Usman F; Nopparat J; Javed I; Srichana T
    Drug Deliv Transl Res; 2020 Feb; 10(1):59-69. PubMed ID: 31368043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of novel oral lipid-based formulations of amphotericin B using an in vitro lipolysis model.
    Ibrahim F; Gershkovich P; Sivak O; Wasan EK; Wasan KM
    Eur J Pharm Sci; 2012 Aug; 46(5):323-8. PubMed ID: 22369857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gelatin coated hybrid lipid nanoparticles for oral delivery of amphotericin B.
    Jain S; Valvi PU; Swarnakar NK; Thanki K
    Mol Pharm; 2012 Sep; 9(9):2542-53. PubMed ID: 22845020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biodistribution and
    Iman M; Huang Z; Alavizadeh SH; Szoka FC; Jaafari MR
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the Safety, Tolerability, Pharmacokinetics, and Biodistribution of Novel Oral Formulations of Amphotericin B following Single- and Multiple-Dose Administration to Beagle Dogs.
    Wasan KM; Wasan EK; Hnik P
    Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32816728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new nanoemulsion formulation improves antileishmanial activity and reduces toxicity of amphotericin B.
    Santos DCMD; de Souza MLS; Teixeira EM; Alves LL; Vilela JMC; Andrade M; Carvalho MDG; Fernandes AP; Ferreira LAM; Aguiar MMG
    J Drug Target; 2018 Apr; 26(4):357-364. PubMed ID: 29041824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amphotericin B loaded ethyl cellulose nanoparticles with magnified oral bioavailability for safe and effective treatment of fungal infection.
    Kaur K; Kumar P; Kush P
    Biomed Pharmacother; 2020 Aug; 128():110297. PubMed ID: 32480227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of the toxicity of a new lipid complex formulation of amphotericin B.
    Larabi M; Pages N; Pons F; Appel M; Gulik A; Schlatter J; Bouvet S; Barratt G
    J Antimicrob Chemother; 2004 Jan; 53(1):81-8. PubMed ID: 14657087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation of amphotericin B as nanosuspension for oral administration.
    Kayser O; Olbrich C; Yardley V; Kiderlen AF; Croft SL
    Int J Pharm; 2003 Mar; 254(1):73-5. PubMed ID: 12615413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the efficacy and toxicity of amphotericin B incorporated in lipid nano-sphere (LNS).
    Fukui H; Koike T; Saheki A; Sonoke S; Tomii Y; Seki J
    Int J Pharm; 2003 Sep; 263(1-2):51-60. PubMed ID: 12954180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.